Alcon Labs Inc Drug Patent Portfolio
Alcon Labs Inc owns 7 orange book drugs protected by 47 US patents with Pataday Twice Daily Relief having the least patent protection, holding only 2 patents. And Rocklatan with maximum patent protection, holding 17 patents. Given below is the list of Alcon Labs Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10588901 | Combination therapy | 14 Mar, 2034 | Active |
| US11020385 | Combination therapy | 14 Mar, 2034 | Active |
| US11185538 | Compositions for treating glaucoma or reducing intraocular pressure | 14 Mar, 2034 | Active |
| US9415043 | Combination therapy | 14 Mar, 2034 | Active |
| US9931336 | Combination therapy | 14 Mar, 2034 | Active |
| US11197853 | Combination therapy | 14 Mar, 2034 | Active |
| US9993470 | Combination therapy | 14 Mar, 2034 | Active |
| US10058511 | Nanocrystals, compositions, and methods that aid particle transport in mucus | 03 May, 2033 | Active |
| US10646436 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US10688045 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US10857096 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US10940108 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US10945948 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US10993908 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US11219596 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US11596599 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US11642317 | Nanocrystals, compositions, and methods that aid particle transport in mucus | 03 May, 2033 | Active |
| US11872318 | Nanocrystals, compositions, and methods that aid particle transport in mucus | 03 May, 2033 | Active |
| US9056057 | Nanocrystals, compositions, and methods that aid particle transport in mucus | 03 May, 2033 | Active |
| US9393213 | Nanocrystals, compositions, and methods that aid particle transport in mucus | 03 May, 2033 | Active |
| US9532955 | Nanocrystals, compositions, and methods that aid particle transport in mucus | 03 May, 2033 | Active |
| US9737491 | Nanocrystals, compositions, and methods that aid particle transport in mucus | 03 May, 2033 | Active |
| US9827191 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US10646437 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US10864219 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US11219597 | Compositions and methods for ophthalmic and/or other applications | 03 May, 2033 | Active |
| US8791154 | High concentration olopatadine ophthalmic composition | 19 May, 2032 | Active |
| US9533053 | High concentration olopatadine ophthalmic composition | 19 May, 2032 | Active |
| US8394826 | Dual mechanism inhibitors for the treatment of disease | 10 Nov, 2030 | Active |
| US9044484 | Aqueous pharmaceutical compositions containing borate-polyol complexes | 30 Oct, 2030 | Active |
| US9421265 | Aqueous pharmaceutical compositions containing borate-polyol complexes | 17 Jun, 2030 | Active |
| US10174017 | Dual mechanism inhibitors for the treatment of disease | 27 Jan, 2030 | Active |
| US10654844 | Dual mechanism inhibitors for the treatment of disease | 27 Jan, 2030 | Active |
| US11028081 | Dual mechanism inhibitors for the treatment of disease | 27 Jan, 2030 | Active |
| US11618748 | Dual mechanism inhibitors for the treatment of disease | 27 Jan, 2030 | Active |
| US10532993 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | 11 Jul, 2026 | Active |
| US10882840 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | 11 Jul, 2026 | Active |
| US11021456 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | 11 Jul, 2026 | Active |
| US8450344 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | 11 Jul, 2026 | Active |
| US9096569 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | 11 Jul, 2026 | Active |
| US6995186 | Olopatadine formulations for topical administration | 12 May, 2024 | Expired |
| US6995186 | Olopatadine formulations for topical administration | 12 Nov, 2023 | Expired |
| US7402609 | Olopatadine formulations for topical administration | 19 Dec, 2022 | Expired |
| US7402609 | Olopatadine formulations for topical administration | 19 Jun, 2022 | Expired |
| US6316441 | Brinzolamide and brimonidine for treating glaucoma | 07 Dec, 2019 | Expired |
| US5641805 | Topical ophthalmic formulations for treating allergic eye diseases | 06 Dec, 2015 | Expired |
| US5641805 | Topical ophthalmic formulations for treating allergic eye diseases | 06 Jun, 2015 | Expired |
Latest Legal Activities on Alcon Labs Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Alcon Labs Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jun, 2024 | US10882840 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jun, 2024 | US10882840 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9532955 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9532955 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jun, 2024 | US9533053 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 May, 2024 | US10864219 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 May, 2024 | US10857096 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US9415043 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US10174017 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US8394826 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US10058511 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US10058511 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US9532955 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US9532955 |
|
Correspondence Address Change
Critical
| 25 Mar, 2024 | US8450344 |
Alcon Labs Inc's Drug Patent Litigations
Alcon Labs Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 18, 2016, against patent number US8791154. The petitioner Apotex, Inc., challenged the validity of this patent, with Alcon Research, Ltd. as the respondent. Click below to track the latest information on how companies are challenging Alcon Labs Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9533053 | December, 2019 |
Terminated-Denied
(06 Aug, 2020)
| Novartis AG | AYLA PHARMA LLC |
| US8791154 | June, 2018 |
Terminated-Settled
(17 Sep, 2018)
| Alcon Research Ltd. | Cipla Limited |
| US9533053 | June, 2018 |
Terminated-Settled
(17 Sep, 2018)
| Alcon Research Ltd. | Cipla Limited |
| US8791154 | February, 2016 |
Terminated-Settled
(30 Nov, 2016)
| Alcon Research, Ltd. | Argentum Pharmaceuticals, LLC |
| US8791154 | August, 2016 |
Terminated-Settled
(30 Nov, 2016)
| Alcon Research, Ltd. | Apotex, Inc. |
Alcon Labs Inc Drug Patents' Oppositions Filed in EPO
Alcon Labs Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 22, 2014, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP10727317A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP18206195A | Aug, 2021 | df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB | Granted and Under Opposition |
| EP18206195A | Aug, 2021 | Isarpatent - Patent- und Rechtsanwälte Barth Charles Hassa Peckmann und Partner mbB | Granted and Under Opposition |
| EP18206195A | Aug, 2021 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP16159225A | Jan, 2021 | Generics [UK] Limited | Granted and Under Opposition |
| EP14150805A | Jan, 2017 | Generics (U.K.) Limited | Granted and Under Opposition |
| EP14150805A | Jan, 2017 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP10727317A | Jan, 2015 | Generics [UK] Ltd (trading as Mylan) | Revoked |
| EP10727317A | Dec, 2014 | Teva Pharmaceutical Industries LTD. | Revoked |
Alcon Labs Inc's Family Patents
Alcon Labs Inc drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 32.0% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Alcon Labs Inc Drug List
Given below is the complete list of Alcon Labs Inc's drugs and the patents protecting them.
1. Eysuvis
Eysuvis is protected by 16 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10058511 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US10646436 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US10688045 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US10857096 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US10940108 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US10945948 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US10993908 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US11219596 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US11596599 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US11642317 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US11872318 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9056057 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9393213 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9532955 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9737491 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9827191 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eysuvis's drug page
2. Inveltys
Inveltys is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10058511 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US10646437 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US10688045 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US10864219 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US11219597 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
| US11642317 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US11872318 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9056057 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9393213 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9532955 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9737491 | Nanocrystals, compositions, and methods that aid particle transport in mucus |
03 May, 2033
(8 years from now)
| Active |
| US9827191 | Compositions and methods for ophthalmic and/or other applications |
03 May, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inveltys's drug page
3. Pataday Once Daily Relief
Pataday Once Daily Relief is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8791154 | High concentration olopatadine ophthalmic composition |
19 May, 2032
(7 years from now)
| Active |
| US9533053 | High concentration olopatadine ophthalmic composition |
19 May, 2032
(7 years from now)
| Active |
| US6995186
(Pediatric)
| Olopatadine formulations for topical administration |
12 May, 2024
(6 months ago)
| Expired |
| US6995186 | Olopatadine formulations for topical administration |
12 Nov, 2023
(1 year, 10 days ago)
| Expired |
| US7402609
(Pediatric)
| Olopatadine formulations for topical administration |
19 Dec, 2022
(1 year, 11 months ago)
| Expired |
| US7402609 | Olopatadine formulations for topical administration |
19 Jun, 2022
(2 years ago)
| Expired |
| US5641805
(Pediatric)
| Topical ophthalmic formulations for treating allergic eye diseases |
06 Dec, 2015
(8 years ago)
| Expired |
| US5641805 | Topical ophthalmic formulations for treating allergic eye diseases |
06 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pataday Once Daily Relief's drug page
4. Pataday Twice Daily Relief
Pataday Twice Daily Relief is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5641805
(Pediatric)
| Topical ophthalmic formulations for treating allergic eye diseases |
06 Dec, 2015
(8 years ago)
| Expired |
| US5641805 | Topical ophthalmic formulations for treating allergic eye diseases |
06 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pataday Twice Daily Relief's drug page
5. Rhopressa
Rhopressa is protected by 15 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10588901 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US11020385 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US11185538 | Compositions for treating glaucoma or reducing intraocular pressure |
14 Mar, 2034
(9 years from now)
| Active |
| US9415043 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US9931336 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US8394826 | Dual mechanism inhibitors for the treatment of disease |
10 Nov, 2030
(5 years from now)
| Active |
| US10174017 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US10654844 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US11028081 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US11618748 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US10532993 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US10882840 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US11021456 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US8450344 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US9096569 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rhopressa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Rocklatan
Rocklatan is protected by 17 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10588901 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US11020385 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US11185538 | Compositions for treating glaucoma or reducing intraocular pressure |
14 Mar, 2034
(9 years from now)
| Active |
| US11197853 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US9415043 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US9931336 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US9993470 | Combination therapy |
14 Mar, 2034
(9 years from now)
| Active |
| US8394826 | Dual mechanism inhibitors for the treatment of disease |
10 Nov, 2030
(5 years from now)
| Active |
| US10174017 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US10654844 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US11028081 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US11618748 | Dual mechanism inhibitors for the treatment of disease |
27 Jan, 2030
(5 years from now)
| Active |
| US10532993 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US10882840 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US11021456 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US8450344 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
| US9096569 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
11 Jul, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rocklatan's drug page
7. Simbrinza
Simbrinza is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9044484 | Aqueous pharmaceutical compositions containing borate-polyol complexes |
30 Oct, 2030
(5 years from now)
| Active |
| US9421265 | Aqueous pharmaceutical compositions containing borate-polyol complexes |
17 Jun, 2030
(5 years from now)
| Active |
| US6316441 | Brinzolamide and brimonidine for treating glaucoma |
07 Dec, 2019
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Simbrinza's drug page